Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farrah Newman

Ophthalmology Jackson, MS Medical Doctor

NPI 1568673689 CMS profile 343184

1190 N State St, Suite 403, Jackson, MS 39202

Open in the dashboard

General payments

$4,330

156 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farrah Newman of Jackson, MS is reported in the CMS Open Payments database as having received $4,330 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $924 27
2024 General $730 18
2023 General $814 29
2022 General $799 33
2021 General $373 19
2020 General $369 20
2019 General $322 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farrah Newman
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Farrah Newman were reported at $924. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Farrah Newman Ophthalmology median Middle half National median
2019 $322 $258 $104–$655 $163
2020 $369 $126 $45–$321 $114
2021 $373 $205 $76–$534 $132
2022 $799 $266 $100–$678 $149
2023 $814 $308 $117–$745 $160
2024 $730 $340 $127–$846 $164
2025 $924 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,440 39 payments
  2. AbbVie, Inc. $731 26 payments
  3. Novartis Pharmaceuticals Corporation $429 26 payments
  4. Mallinckrodt Hospital Products Inc. $409 14 payments
  5. Oyster Point Pharma, Inc. $292 8 payments
  6. Allergan Inc. $289 11 payments
  7. Sun Pharmaceutical Industries Inc. $134 7 payments
  8. Bausch & Lomb, a division of Bausch Health US, LLC $128 3 payments
  9. Amgen Inc. $110 2 payments
  10. TissueTech, Inc. $66 4 payments
  11. Other $302 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,330 156 payments
Products named General payments · program years 2019–2025
  1. Clareon Ophthalmology $500 14 payments
  2. XIIDRA $447 27 payments
  3. ACTHAR $409 14 payments
  4. Clareon Ophthalmology $314 7 payments
  5. TYRVAYA $268 7 payments
  6. Clareon PanOptix Pro $235 5 payments
  7. DURYSTA Glaucoma $234 8 payments
  8. VUITY $206 7 payments
  9. DURYSTA Eye Care $197 11 payments
  10. Clareon Ophthalmology $174 1 payment
  11. Other $1,796 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

91

Median for Ophthalmology: 891

Drug cost

$798

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 76 $701
Brimonidine Tartrate Generic 15 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$28,569

Medicare's payments for the services billed

Medicare patients

163

Average age 74

Services billed

349

110 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 54%
Diabetes 26%
Ischemic heart disease 21%
Depression 19%
Chronic kidney disease 17%
Atrial fibrillation 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $88
$88 — —
DURYSTA
  • AbbVie, Inc. $52
$52 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $52
$52 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $25
$25 — —
MIEBO
  • Bausch & Lomb Americas Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record